CA2796744A1 - Metabolites synthetiques d'omega-carboxyaryldiphenylurees fluorosubstituees pour le traitement et la prevention de maladies et d'etats - Google Patents

Metabolites synthetiques d'omega-carboxyaryldiphenylurees fluorosubstituees pour le traitement et la prevention de maladies et d'etats Download PDF

Info

Publication number
CA2796744A1
CA2796744A1 CA2796744A CA2796744A CA2796744A1 CA 2796744 A1 CA2796744 A1 CA 2796744A1 CA 2796744 A CA2796744 A CA 2796744A CA 2796744 A CA2796744 A CA 2796744A CA 2796744 A1 CA2796744 A1 CA 2796744A1
Authority
CA
Canada
Prior art keywords
synthetic
formula
metabolites
diseases
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2796744A
Other languages
English (en)
Inventor
Scott Wilhelm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Original Assignee
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare LLC filed Critical Bayer Healthcare LLC
Publication of CA2796744A1 publication Critical patent/CA2796744A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
CA2796744A 2010-04-17 2011-04-18 Metabolites synthetiques d'omega-carboxyaryldiphenylurees fluorosubstituees pour le traitement et la prevention de maladies et d'etats Abandoned CA2796744A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32529410P 2010-04-17 2010-04-17
US61/325,294 2010-04-17
PCT/US2011/032835 WO2011130728A1 (fr) 2010-04-17 2011-04-18 Métabolites synthétiques d'oméga-carboxyaryldiphénylurées fluorosubstituées pour le traitement et la prévention de maladies et d'états

Publications (1)

Publication Number Publication Date
CA2796744A1 true CA2796744A1 (fr) 2011-10-20

Family

ID=44144967

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2796744A Abandoned CA2796744A1 (fr) 2010-04-17 2011-04-18 Metabolites synthetiques d'omega-carboxyaryldiphenylurees fluorosubstituees pour le traitement et la prevention de maladies et d'etats

Country Status (3)

Country Link
CN (1) CN103079567A (fr)
CA (1) CA2796744A1 (fr)
WO (1) WO2011130728A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102643229A (zh) * 2012-01-17 2012-08-22 湖南有色凯铂生物药业有限公司 N-((4-氯-3-三氟甲基)苯基)-n’-((2-氟-4-(2-氨基甲酰基)-4-吡啶基氧)苯基)脲及其作为抗癌药物的应用
CN102885814A (zh) * 2012-01-17 2013-01-23 湖南有色凯铂生物药业有限公司 一种化合物及其作为抗癌药物的应用
CN103508944A (zh) * 2012-06-25 2014-01-15 湖南有色凯铂生物药业有限公司 N-((4-氯-3-三氟甲基)苯基)-n’-((2-氟-4-(2-氨基甲酰基)-4-吡啶基氧)苯基)脲的晶型a及其制备方法
CN103058922B (zh) * 2012-09-06 2014-07-16 湖南有色凯铂生物药业有限公司 用于抗肿瘤药物的芳香脲的晶型及其制备方法
CN104250226B (zh) * 2013-06-27 2019-04-26 常州方楠医药技术有限公司 一种制备瑞格菲尼中间体的方法
CN104736521B (zh) * 2013-09-12 2016-10-12 杭州普晒医药科技有限公司 瑞格非尼盐晶型及其制备方法和用途
CN103923001B (zh) * 2014-04-30 2016-02-10 药源药物化学（上海）有限公司 瑞戈非尼盐及其晶型、制备方法
CN105218439B (zh) * 2014-06-06 2018-11-20 连云港润众制药有限公司 一种瑞格非尼的晶体及其制备方法
CN105566215B (zh) * 2014-10-17 2018-02-16 沈阳药科大学 一种瑞戈非尼的制备方法
CN104592105B (zh) * 2015-02-10 2017-01-18 杭州朱养心药业有限公司 瑞戈非尼及其制法
CN107921173B (zh) * 2015-08-03 2021-07-06 富士胶片株式会社 细胞结构体、非人模型动物、非人模型动物的制造方法及被检验物质的评价方法
CN109796401B (zh) * 2019-04-04 2023-10-17 新乡双鹭药业有限公司 一种瑞戈非尼原料药的制备方法
CN112587485A (zh) * 2021-01-08 2021-04-02 湖南南新制药股份有限公司 一种药物固体分散体及其制备方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4220302A (en) 1978-07-21 1980-09-02 Hampton Diane M Nursing bottle holder
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US6040166A (en) 1985-03-28 2000-03-21 Roche Molecular Systems, Inc. Kits for amplifying and detecting nucleic acid sequences, including a probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
IL86724A (en) 1987-06-19 1995-01-24 Siska Diagnostics Inc Methods and kits for amplification and testing of nucleic acid sequences
AU622426B2 (en) 1987-12-11 1992-04-09 Abbott Laboratories Assay using template-dependent nucleic acid probe reorganization
CA1340807C (fr) 1988-02-24 1999-11-02 Lawrence T. Malek Procede d'amplification d'une sequence d'acide nucleique
US6054270A (en) 1988-05-03 2000-04-25 Oxford Gene Technology Limited Analying polynucleotide sequences
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
DE3938907C2 (de) 1989-11-24 1999-11-04 Dade Behring Marburg Gmbh Mittel zum Lagern und Suspendieren von Zellen, insbesondere Erythrozyten
US5192744A (en) 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
CA2036946C (fr) 1990-04-06 2001-10-16 Kenneth V. Deugau Molecules de liaison pour indexation
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
WO1992007095A1 (fr) 1990-10-15 1992-04-30 Stratagene Procede de reaction en chaine de polymerase arbitrairement amorcee destine a produire une empreinte genetique de genomes
EP0562025B1 (fr) 1990-12-06 2001-02-07 Affymetrix, Inc. (a Delaware Corporation) Substances et leur utilisation pour un strategie binaire de la synthése
DE69231853T2 (de) 1991-11-07 2001-09-13 Nanotronics Inc Hybridisierung von mit chromophoren und fluorophoren konjugierten polynukleotiden zur erzeugung eines donor-zu-donor energietransfersystems
US5348853A (en) 1991-12-16 1994-09-20 Biotronics Corporation Method for reducing non-specific priming in DNA amplification
ATE231920T1 (de) 1992-03-11 2003-02-15 Dana Farber Cancer Inst Inc Methode um mrna zu klonieren
US5262311A (en) 1992-03-11 1993-11-16 Dana-Farber Cancer Institute, Inc. Methods to clone polyA mRNA
AU5298393A (en) 1992-10-08 1994-05-09 Regents Of The University Of California, The Pcr assays to determine the presence and concentration of a target
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5871918A (en) 1996-06-20 1999-02-16 The University Of North Carolina At Chapel Hill Electrochemical detection of nucleic acid hybridization
US5837682A (en) 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
CA2159830C (fr) 1994-04-29 2001-07-03 Timothy M Woudenberg Systeme de detection en temps reel de produits d'amplification d'acides nucleiques
US5723290A (en) 1994-11-03 1998-03-03 Trustees Of The University Of Pennsylvania Methods for profiling mRNA expression in neurites
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5994063A (en) 1995-06-23 1999-11-30 Metzker; Michael L. Substituted 4,4-difluoro-4-bora-3A,4A-diaza-s-indacene compounds for homogenous amplification/detection assays
US5712126A (en) 1995-08-01 1998-01-27 Yale University Analysis of gene expression by display of 3-end restriction fragments of CDNA
DE69630142D1 (de) 1995-11-16 2003-10-30 Baylor College Medicine Verfahren zur identifizierung metastatischer sequenzen
DE69726281T2 (de) 1996-03-25 2004-08-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält
US6117635A (en) 1996-07-16 2000-09-12 Intergen Company Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
WO1998005293A2 (fr) 1996-08-02 1998-02-12 The Children's Medical Center Corporation Procede de regulation du systeme reproductif femelle au moyen d'inhibiteurs de l'angiogenese
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
WO2000042012A1 (fr) 1999-01-13 2000-07-20 Bayer Corporation DIPHENYLUREES A SUBSTITUANTS φ-CARBOXYARYLES, INHIBITRICES DE KINASE RAF
EP2298311B1 (fr) 1999-01-13 2012-05-09 Bayer HealthCare LLC Urées de diphényle à substitution omega-carboxyaryle en tant qu'inhibiteurs de la p38 kinase
JP3789066B2 (ja) 1999-12-08 2006-06-21 三菱電機株式会社 液晶表示装置
US8725620B2 (en) 2000-07-10 2014-05-13 Nobuyoshi Morimoto System and method for negotiating improved terms for products and services being purchased through the internet
CA2430180C (fr) 2003-05-21 2010-03-16 Royal Group Technologies Limited Store a elements horizontaux en cascade
UA84156C2 (ru) * 2003-07-23 2008-09-25 Байер Фармасьютикалс Корпорейшн Фторозамещённая омега-карбоксиарилдифенилмочевина для лечения и профилактики болезней и состояний
CA2628849A1 (fr) * 2005-11-10 2007-05-18 Bayer Healthcare Ag Diaryle-uree permettant de traiter l'hypertension pulmonaire
WO2007068380A1 (fr) * 2005-12-15 2007-06-21 Bayer Healthcare Ag Diaryle-uree pour le traitement d'infections virales
GB0614498D0 (en) * 2006-07-21 2006-08-30 Univ Belfast Improvements in Hydrogen Trapping
US8680124B2 (en) * 2007-01-19 2014-03-25 Bayer Healthcare Llc Treatment of cancers with acquired resistance to kit inhibitors
JP2010516692A (ja) * 2007-01-19 2010-05-20 バイエル・ヘルスケア・エルエルシー 化学療法剤に対し抵抗性を有する癌の処置
US8312249B1 (en) 2008-10-10 2012-11-13 Apple Inc. Dynamic trampoline and structured code generation in a signed code environment
US9993647B2 (en) 2014-12-31 2018-06-12 Tsinghua University Variable frequency stimulation therapy method

Also Published As

Publication number Publication date
WO2011130728A1 (fr) 2011-10-20
CN103079567A (zh) 2013-05-01

Similar Documents

Publication Publication Date Title
CA2796744A1 (fr) Metabolites synthetiques d'omega-carboxyaryldiphenylurees fluorosubstituees pour le traitement et la prevention de maladies et d'etats
PH12018502364A1 (en) Novel compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
EP4023641A3 (fr) Procédé de synthèse d'analogues de l'hormone thyroïdienne et de ses polymorphes
UY33587A (es) Nuevos compuestos como inhibidores de quinasas syk y jak
PH12015500211A1 (en) 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
PH12015501585A1 (en) Manufacturing process for pyrimidine derivatives
AR080819A1 (es) Sintesis estereoselectiva de activos que contienen fosforo
UA108645C2 (uk) Композиція для боротьби з хворобами рослин і її застосування
MX2012013332A (es) Preparacion de intermediarios de posaconazol.
IN2014MN02082A (fr)
WO2014041559A3 (fr) Procédé de préparation d'étéxilate de dabigatran et ses intermédiaires
MX2010009860A (es) Sintesis total de salinosporamida a y sus analogos.
UA110128C2 (uk) Індолкарбоксаміди та бензімідазолкарбоксаміди як інсектициди та акарициди
IN2014DN07224A (fr)
WO2013093931A3 (fr) Nouveaux promédicaments de médicaments phénoliques
CA2859282C (fr) Derives de strigolactame en tant que composes regulateurs de la croissance des plantes
EP2586785A4 (fr) Composé de type ester d'acide phosphorique d'un ester phénylique substitué par un hydroxyacide, son procédé de synthèse et son utilisation médicale
IN2014DN07220A (fr)
WO2012107735A3 (fr) Traitement de trouble bipolaire
IN2014DN07954A (fr)
WO2012071562A3 (fr) Procédés de criblage de composés qui sont cytotoxiques pour des cellules tumorales et procédés de traitement de cellules tumorales utilisant un tel composé
MD4190C1 (ro) Inhibitor al leucemiei mieloide umane în bază de {bis[2-(3,5-dibromo-2-hidroxifenil)-2-oxoetil-piperidin-1-carboditioato(1-)-O,O']cupru}
GB201020255D0 (en) Organic compounds
MX2013005165A (es) Formas cristalinas de un acido alcoxiimidazol-1-ilmetil bifenil carboxilico.
WO2013026866A3 (fr) Nouveaux microbiocides

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20170418